Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy
Bisphosphonates are therapeutic agents that have been used for almost five decades in the treatment of various bone diseases, such as osteoporosis, Paget disease and prevention of osseous complications in cancer patients. In nuclear medicine, simple bisphosphonates such as <sup>99m</sup>...
Main Authors: | Céleste Souche, Juliette Fouillet, Léa Rubira, Charlotte Donzé, Emmanuel Deshayes, Cyril Fersing |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/25/1/462 |
Similar Items
-
Production of Medical Radionuclides in the Center for Radiopharmaceutical Tumor Research—A Status Report
by: Martin Kreller, et al.
Published: (2024-02-01) -
Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with <sup>68</sup>Ga and <sup>177</sup>Lu as Potential Theranostic Agent for Colon Cancer
by: Radu Anton Leonte, et al.
Published: (2021-04-01) -
Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results
by: Ambreen Khawar, et al.
Published: (2019-11-01) -
AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
by: Cyril Fersing, et al.
Published: (2022-02-01) -
[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)